STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #467 by analyst upside · 2026-09-16
CAPR
Capricor Therapeutics, Inc.
Healthcare · Market Cap $498M · P/E 0x
ANALYST PRICE TARGET
+215.4%
implied upside to consensus target
Current Price $8.56
Consensus Target $27.0
Bull Target $54.0
Bear Target $7.0
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
2
Hold
3
Sell
0
52-Week Low $2.96
52-Week High $40.37
YTD Return -69.8%
FUNDAMENTALS
Market Cap $498M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.38
PEG Ratio 0.38
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.96
52-Week High $40.37
Current Price $8.56
Bear Target $7.0
Bull Target $54.0
● Now $8.56 ● Target $27.0
TRADING DATA
Avg Volume 6.5M
YTD Return -69.8%
Analyst Count 5
Consensus Hold
Upside to Target +215.4%
Last Updated 2026-09-16

ANALYST SUMMARY

Capricor Therapeutics, Inc. (CAPR) is currently trading at $8.56 with a Wall Street consensus price target of $27.0, implying potential upside of 215.4% over the next 12 months. 5 analysts currently cover CAPR, with a consensus rating of Hold - 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $54.0, while the most cautious has a target of $7.0.

CAPR operates in the Healthcare sector with a market capitalisation of $498M. The stock is down 69.8% year-to-date and is currently trading near the lower end of its 52-week range of $2.96 – $40.37.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CAPR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler ↑ Upgrade
Neutral → Overweight 2026-09-01 14% win rate (7 calls)
Cantor Fitzgerald ↑ Upgrade
Neutral → Overweight 2026-08-14 40% win rate (10 calls)
Jones Trading ↓ Downgrade
Buy → Hold 2026-07-31 57% win rate (14 calls)
Piper Sandler ↓ Downgrade
Overweight → Neutral 2026-07-30 14% win rate (7 calls)
Cantor Fitzgerald ↓ Downgrade
Overweight → Neutral 2026-07-30 40% win rate (10 calls)
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-07-30 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-13 31% win rate (48 calls)
B. Riley Securities - Reiterated
Buy → Buy 2026-03-13 17% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
21
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →